

## Ko 143

**Catalog No: tcsc0298**



### Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

---

**CAS No:**

461054-93-3

**Formula:**

$C_{26}H_{35}N_3O_5$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

BCRP

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O :

**Observed Molecular Weight:**

469.57


### Product Description

Ko 143 is a practical breast cancer resistance protein multidrug transporter inhibitor **BCRP**, with the **EC<sub>90</sub>** value of 26 nM.

IC50 & Target: EC90: 26 nM (BCRP)

**In Vitro:** Ko143 (10 nM) significantly decreases (2.5-fold) the IC<sub>50</sub> of MTX for HEK G2 cells and mouse G2 cells. Ko143 (1-100 μM) metabolite does not inhibit the function of ABC Transporters<sup>[1]</sup>. Reversal of drug resistance in topotecan-selected mouse MEF3.8/T6400 cells and human IGROV1/T8 cells by FTC analogue Ko143. Ko143 is applied at zero, one, or eight times the EC<sub>90</sub> concentration of 25 nM<sup>[2]</sup>. Ko143 inhibits BCRP-mediated transport of rosuvastatin in Madin-Darby Canine Kidney (MDCK) 2-BCRP421CC (wild type) cells and MDCK2-BCRP421AA (mutant type) cells<sup>[3]</sup>.

**In Vivo:** Ko143 (10 mg/kg, p.o.) increases the oral availability of topotecan in mice<sup>[2]</sup>. Ko143 significantly affects the pharmacokinetics of rosuvastatin in rats<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!